Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05236036 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05236036 · ClinicalTrials.gov record · last posted 2026-08-26

Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma

StatusActive, Not Recruiting
PhasePhase 1
Started2022-08-08
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This phase I/Ib trial tests the safety, side effects, and best dose of mycophenolate mofetil in combination with temozolomide and/or radiation therapy (standard of care) in treating patients with glioblastoma. Mycophenolate mofetil is an immunosuppressant drug that is typically used to prevent organ rejection in transplant recipients. However, mycophenolate mofetil may also help chemotherapy with temozolomide work better by making tumor cells more sensitive to the drug. The purpose of this trial is to determine if mycophenolate mofetil combined with temozolomide can stop glioblastoma.

Protocol amendment history 3 changes detected by DataLookout

2026-08-27
Enrollment increased: 60 → 86 participants
2026-08-27
Trial arms changed: 4 → 5
2026-08-27
Primary completion pushed: 2026-01-12 → 2029-01-03
Trial Details
NCT Number NCT05236036
Lead Sponsor Northwestern University
Collaborators: National Cancer Institute (NCI)
Conditions Astrocytoma, Glioblastoma, Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma, Recurrent Glioblastoma
Enrollment 86 participants
Start Date 2022-08-08
Primary Completion 2029-01-03 (estimated)
Study Completion 2029-01-03 (estimated)
Updated on ClinicalTrials.gov 2026-08-26